Christopher Raymond
Stock Analyst at Piper Sandler
(2.53)
# 2,199
Out of 4,843 analysts
135
Total ratings
50.46%
Success rate
-1.38%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $132.75 | -13.37% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $0.47 | +1,826.37% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $58.55 | +115.20% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $1.89 | +111.64% | 3 | Feb 11, 2025 | |
| ARDX Ardelyx | Maintains: Neutral | $7 → $8 | $4.03 | +98.51% | 7 | Jan 27, 2025 | |
| BPMC Blueprint Medicines | Maintains: Neutral | $109 → $119 | $103.06 | +15.47% | 4 | Jan 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $447.09 | +19.22% | 8 | Jan 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,195 → $1,013 | $605.39 | +67.33% | 7 | Jan 27, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $135 → $140 | $35.04 | +299.54% | 5 | Jan 13, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $43 → $30 | $3.95 | +659.49% | 1 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $31.88 | +125.85% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $220 | $185.62 | +18.52% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $1.46 | +790.41% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $4.49 | +1,570.38% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $14.74 | +415.60% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $1.21 | +726.45% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $9.25 | +256.76% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $2.75 | +154.55% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $5.98 | +602.93% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $5.51 | +299.27% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $3.01 | +32.89% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $5.36 | +366.42% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $283.54 | +1.57% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $31.84 | +28.77% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $58.84 | -52.41% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $74.79 | -46.52% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $3.30 | +2,627.27% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $2.13 | +4,407.04% | 2 | Mar 13, 2020 |
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $132.75
Upside: -13.37%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $0.47
Upside: +1,826.37%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $58.55
Upside: +115.20%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $1.89
Upside: +111.64%
Ardelyx
Jan 27, 2025
Maintains: Neutral
Price Target: $7 → $8
Current: $4.03
Upside: +98.51%
Blueprint Medicines
Jan 27, 2025
Maintains: Neutral
Price Target: $109 → $119
Current: $103.06
Upside: +15.47%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $447.09
Upside: +19.22%
Regeneron Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $605.39
Upside: +67.33%
Ultragenyx Pharmaceutical
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $35.04
Upside: +299.54%
Inozyme Pharma
Jan 13, 2025
Maintains: Overweight
Price Target: $43 → $30
Current: $3.95
Upside: +659.49%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $31.88
Upside: +125.85%
Dec 17, 2024
Maintains: Overweight
Price Target: $212 → $220
Current: $185.62
Upside: +18.52%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $1.46
Upside: +790.41%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $4.49
Upside: +1,570.38%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $14.74
Upside: +415.60%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $1.21
Upside: +726.45%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $9.25
Upside: +256.76%
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $2.75
Upside: +154.55%
Apr 29, 2024
Initiates: Overweight
Price Target: $42
Current: $5.98
Upside: +602.93%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $5.51
Upside: +299.27%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $3.01
Upside: +32.89%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $5.36
Upside: +366.42%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $283.54
Upside: +1.57%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $31.84
Upside: +28.77%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $58.84
Upside: -52.41%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $74.79
Upside: -46.52%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $3.30
Upside: +2,627.27%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $2.13
Upside: +4,407.04%